Rockwell Medical (RMTI) Q4 2024 earnings summary

Executive summary

• Achieved record net sales of $101.5 million in 2024, a 21% year-over-year increase, surpassing the $100 million target.

• Gross margin improved to 17% for the full year, up from 10% in 2023, with gross profit reaching $17.5 million, more than double 2023.

• Achieved profitability on an adjusted EBITDA basis for the first time, with $5.2 million in 2024.

• Net loss narrowed to $0.5 million for 2024, a 94% improvement from 2023.

• 2025 is expected to be a transition year due to the loss of the largest customer, with a projected $34 million revenue decline.

Financial highlights

• Q4 2024 net sales were $24.7 million, up 12% year-over-year; full year net sales reached $101.5 million, up 21%.

• Q4 2024 gross profit was $3.6 million (27% increase); full year gross profit was $17.5 million (over double 2023).

• Q4 2024 net loss was $800,000 (50% improvement); full year net loss was $500,000 (improved by nearly $8 million).

• Adjusted EBITDA for Q4 2024 was $1.4 million (156% improvement); full year adjusted EBITDA was $5.2 million (up $9 million from 2023).

• Cash and equivalents at year-end 2024 totaled $21.6 million, up from $10.9 million at end of 2023.

Outlook and guidance

• 2025 net sales projected between $65 million and $70 million; gross margin expected between 16% and 18%.

• Adjusted EBITDA guidance ranges from -$500,000 to +$500,000, aiming for full-year profitability.

• Guidance assumes complete transition of largest customer by June 30, 2025, reducing revenue by $34 million.

• Focus on diversifying customer base, expanding product portfolio, and pursuing new business development opportunities.

• Added single-use bicarbonate cartridge in 2025, targeting a $100 million market opportunity.